A method of managing a speed of implantable blood pump. The implantable blood pump is in communication with an internal battery and a transcutaneous energy transfer system (TETS). The method includes starting the pump at a programmed set speed. The speed of the pump is decreased from the programmed set speed to a minimum set speed if either a capacity of the internal battery is less than a predetermined reserve level and TETS power is unavailable, or there is insufficient TETS power to maintain the programmed set speed. The speed of the pump is progressively decreased from the programmed set speed if there is insufficient power to maintain the programmed set speed.

A blood pump for supporting a patient's heart includes a flow cannula having a distal portion including a distal end and a proximal portion including a proximal end opposite the distal end, the distal end of the flow cannula configured to be connected to the patient's heart or a blood vessel to establish fluid communication between the blood pump and the patient's heart and blood vessel, respectively. The flow cannula further includes an intermediate portion attached to the distal portion and the proximal portion, wherein the intermediate portion allows twisting thereof with a lower force than the distal portion and the proximal portion. The intermediate portion can be fully occluded by twisting it. At least a portion of the intermediate portion either alone or in combination with the distal portion is adapted to be permanently attached to the patient's heart or a blood vessel.

Systems and methods are described for implementing or deploying one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

The disclosure provides an implantable bioartificial active secretion system for providing a physiological regulating secretion such as insulin necessary for functionality of a physiologic activity such as glucose metabolism of a living-being host. The system includes a housing implantable within the host, in fluidic communication with tissue fluid indicative of a physiological regulating secretion need. A chamber within the housing contains a plurality of physiologically active, autonomously functioning, live secretory cells for producing the physiological regulating secretion. A continually operating two pump apparatus moves tissue fluid into contact with the secretory cells for pick up of the physiological regulating secretion for subsequent physiologically-effective dispensing into the host, while avoiding immuno-rejection of the host body or of the host to the secretory cells.

Methods and systems include a long-term implantable ultra-filtrate monitoring system that uses micro-porous membranes to produce an ultra-filtrate of tissue interstitial fluid or blood plasma. The ultra-filtrate is transported through a sensor to detect a level of analyte in the ultra-filtrate. The long-term implantable fluid monitoring system thus includes a first porous catheter, a second porous catheter, a sensor configured to measure an amount of analyte in fluid, and a pump configured to move fluid through the first porous catheter to the sensor and from the sensor through the second porous catheter.

The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.

The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.

An implantable vascular access port for providing repeated therapy to a patient in need of such therapy, the access port, upon repeated use, presents each time an access needle at a new location so as to minimize scarring injury to the skin of the patient. The vascular access port may include a body, a cover comprising a plurality of openings, at least one needle comprising a tip and a shaft, the shaft defining a lumen, a needle elevator mechanism to operate the position of the at least one needle in at least a retracted position in which the at least one needle is disposed in the body and the needle tip below the cover and an extended position in which the at least one needle is engaged through at least a first one of the openings, and a needle shift mechanism to move the at least one needle from a first position in which the needle can engage the at least a first one of the openings, to a second position in which the needle can engage at least a second one of the openings.

A hemofiltration device capable of surely performing highly-efficient hemofiltration. The hemofiltration device of the present invention is adapted to be implanted in a mammalian body for filtering blood, and includes a blood flow path layer having a blood flow path, a filtrate flow path layer having a filtrate flow path disposed along the blood flow path, and a filtration membrane interposed between the blood flow path layer and the filtrate flow path layer, for filtering the blood flowing through the blood flow path. A filtrate outlet of the filtrate flow path is provided at a position closer to a blood outlet than to a blood inlet of the blood flow path. The blood inlet, blood outlet, and filtrate outlet are provided only on one side or separately on opposite sides of a main body portion in the direction in which the layers are stacked.

Mechanical circulatory supports configured to operate in series with the native heart are disclosed. In an embodiment, an intravascular propeller is installed into the descending aorta and anchored within via an expandable anchoring mechanism. The propeller and anchoring mechanism may be foldable so as to be percutaneously deliverable to the aorta. The propeller may have foldable blades. The blades may be magnetic and may be driven by a concentric electromagnetic stator circumferentially outside the magnetic blades. The stator may be intravascular or may be configured to be installed around the outer circumference of the blood vessel. The support may create a pressure rise between about 20-50 mmHg, and maintain a flow rate of about 5 L/min. The support may have one or more pairs of contra-rotating propellers to modulate the tangential velocity of the blood flow. The support may have static pre-swirlers and or de-swirlers. The support may be optimized to replicate naturally occurring vortex formation within the descending aorta.